Market Size in 2024 | Market Forecast in 2034 | CAGR (in %) | Base Year |
---|---|---|---|
USD 3.82 Billion | USD 9.06 Billion | 8.3% | 2024 |
The global high-flow nasal cannula market size was worth around USD 3.82 Billion in 2024 and is predicted to grow to around USD 9.06 Billion by 2034 with a compound annual growth rate (CAGR) of roughly 8.3% between 2025 and 2034. The report analyzes the global high-flow nasal cannula market's drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the high-flow nasal cannula industry.
With up to 60 liters of warm, humidified oxygen delivered per minute, a high flow nasal cannula (HFNC) is a non-invasive respiratory support device, unlike traditional nasal cannulas.
Eliminating carbon dioxide and maybe generating a positive pressure effect can help reduce the effort needed for breathing by increasing the flow rate. The market for high-flow nasal cannulas (HFNCs) is rapidly growing due to their increasing use in the treatment of respiratory conditions across various healthcare environments.
The increasing prevalence of respiratory disease drives market growth
The rising incidence of respiratory diseases is driving the expansion of the High-Flow Nasal Cannulas (HFNCs) market. Globally, this inclination is increasing demand for innovative, non-invasive oxygen delivery technologies, such as HFNC.
Particularly among older people and in areas with high degrees of tobacco use or air pollution, asthma, pneumonia, Chronic Obstructive Pulmonary Disease (COPD), and other respiratory disorders are on the increase. Particularly low- and middle-income countries find that the WHO ranks respiratory diseases third among all causes of death worldwide.
High cost of equipment and setup hinders market growth
Particularly in low- and middle-income nations, one of the main obstacles to the general acceptance of High Flow Nasal Cannula (HFNC) systems is the high equipment and setup costs.
High-performance flow generators, heated humidifiers, wide-bore nasal interfaces, and specialized circuits and filters are just a few of the elements HFNC systems demand. These components taken together make HFNC far more costly than conventional oxygen therapy approaches.
Furthermore, consumables such as sterile water, single-use cannulas, and humidification chambers are routinely replenished. Frequent maintenance, filter replacement, and technical support—all of which HFNC systems also demand—raise lifecycle costs.
Moreover, in certain healthcare systems, the government or insurance companies do not fully reimburse HFNC. Considering unknown financial returns, especially in private or mixed healthcare models, hospitals could be reluctant to use HFNC. All these factors are likely to hamper the expansion of the high flow nasal cannula industry.
Rising collaboration offers a lucrative opportunity for market growth
The increased partnership is probably going to present a lucrative opportunity for the high flow nasal cannula market development over the projection term. For instance, according to a statement released by Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries LTD., the Desert Oasis Healthcare (DOHC) system in California began a respiratory patient monitoring program based on data from Teva's Digihaler System in March 2023.
Working with Rimidi, a top clinical management system focused on enhancing patient experiences, simplifying clinical processes, and fulfilling quality criteria, the program was designed. The first and only intelligent inhaler device available, which provides objective data to patients and doctors to enable better asthma management, is Teva's Digihaler.
The lack of skilled healthcare professionals poses a major challenge to market expansion
Particularly in underdeveloped nations, the High Flow Nasal Cannula (HFNC) sector suffers a major obstacle from the scarcity of qualified healthcare professionals. Because HFNC systems depend on experienced individuals to operate, monitor, and maintain them, their value in low-resource healthcare environments is limited. Up to 60 L/min, HFNC devices enable exact flow rate modifications; they also enable control of FiO2 levels and management of humidity and temperature.
Especially in acute respiratory failure, improper use might lead to insufficient therapy or patient harm. Moreover, several nations lack specialized respiratory therapists entirely. Nurses and general practitioners in low- and middle-income nations sometimes lack formal training in HFNC treatment.
The global high flow nasal cannula industry is segmented based on product type, application, end-user, sales channel, and region.
Based on the product type, the global high flow nasal cannula market is bifurcated into single heated tube, nasal cannula, active humidifier, and air blender. The active humidifier segment is expected to hold the largest market share over the forecast period. The demand for improved patient comfort, clinical effectiveness, and increased acceptance of HFNC therapy in intensive care and emergency settings is driving sector expansion. Furthermore, technical developments are a major component driving segment growth. New active humidifiers have auto-adjusting humidity and temperature, compact and integrated designs, low maintenance, and improved infection control. These advances are propelling hospital improvements and replacements, hence boosting revenue growth.
Based on the application, the global high flow nasal cannula industry is bifurcated into acute respiratory failure, chronic obstructive pulmonary disease, acute heart failure, and others. The acute respiratory failure segment is expected to dominate the market over the projected period. Acute Respiratory Failure (ARF) is a life-threatening condition in which the lungs are unable to supply adequate oxygen to the blood or effectively remove carbon dioxide. It is common in people with pneumonia, COPD exacerbations, acute respiratory distress syndrome (ARDS), and other conditions. For instance, as per the data published by the World Health Organization, chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide.
Based on the end-user, the global market is bifurcated into hospitals and clinics, ambulatory care centers, long-term care centers, and others. The hospitals and clinics segment captures the prominent market share over the projected period. This is driven by their high patient volumes, demand for advanced respiratory support, and adherence to evolving clinical guidelines for non-invasive oxygen therapy.
In terms of Sales Channel, the global high-flow nasal cannula market is categorized into direct channel and distribution channel.
Report Attributes | Report Details |
---|---|
Report Name | High Flow Nasal Cannula Market |
Market Size in 2024 | USD 7.2 Billion |
Market Forecast in 2034 | USD 19.8 Billion |
Growth Rate | CAGR of 10.5% |
Number of Pages | 228 |
Key Companies Covered | Vapotherm Inc., Armstrong Medical Ltd, Teleflex Inc., Salter Labs Inc., ResMed Inc., Becton Dickinson and Company, TNI Medical AG, Smiths Medical, Hamilton Medical AG, Flexicare Medical Ltd, Fisher & Paykel Healthcare Limited, Teijin Pharma Limited, and others. |
Segments Covered | By Product Type, By Application, By End-user, By Sales Channel, and By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA) |
Base Year | 2024 |
Historical Year | 2019 to 2023 |
Forecast Year | 2025 - 2034 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
North America dominates the market over the projected period
North America is expected to dominate the global high flow nasal cannula market. This can be related to the rising prevalence of respiratory disorders such as COPD and asthma, which account for over 80% of healthcare spending due to their chronic nature.
Furthermore, the presence of both local and foreign producers in the region has increased the availability of nasal cannula goods at reasonable rates, propelling market expansion.
Besides, the Asia Pacific is expected to grow at the highest CAGR during the forecast period. This development can be attributed to a number of factors, including a large population, rising healthcare costs, and increased knowledge of respiratory illnesses.
Furthermore, the region's improving healthcare infrastructure, increased access to medical services, and rising demand for home healthcare solutions are propelling the market forward. The nasal cannula market in China presents great growth opportunities due to the country's huge population and high prevalence of chronic respiratory disorders caused by air pollution and other diseases.
The report provides a company market share analysis to give a broader overview of the key market players. In addition, the report also covers key strategic developments of the market, including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the high-flow nasal cannula market on a global and regional basis.
The global high-flow nasal cannula market is dominated by players like:
By Product Type
By Application
By End-user
By Sales Channel
By Region
FrequentlyAsked Questions
With up to 60 liters of warm, humidified oxygen delivered per minute, a high flow nasal cannula (HFNC) is a non-invasive respiratory support device, unlike traditional nasal cannulas.
The global high-flow nasal cannula market is expected to grow due to increasing prevalence of respiratory diseases, a growing geriatric population, and continuous technological advancements in HFNC systems.
According to a study, the global high-flow nasal cannula market size was worth around USD 3.82 Billion in 2024 and is expected to reach USD 9.06 Billion by 2034.
The global high-flow nasal cannula market is expected to grow at a CAGR of 8.3% during the forecast period.
North America is expected to dominate the high-flow nasal cannula market over the forecast period.
Leading players in the global high-flow nasal cannula market include Armstrong Medical Ltd, Salter Labs Inc, ResMed, Inc., Teleflex Inc, Vapotherm Inc., Becton Dickinson, and Company, Smiths Medical, Flexicare Medical Ltd, Teijin Pharma Limited, TNI Medical AG, Fisher & Paykel Healthcare Limited, Hamilton Medical AG, among others.
The report explores crucial aspects of the high-flow nasal cannula market, including a detailed discussion of existing growth factors and restraints, while also examining future growth opportunities and challenges that impact the market.
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed